Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
AFM24: First patient dosed in first-in-human clinical study for advanced EGFR-expressing solid tumors, including colon, lung and other cancersAFM13: Initiated registration-directed study in...
-
AFM24, designed to activate innate immunity to broadly target EGFR-expressing solid tumors regardless of mutational status, has the potential to improve efficacy and safety over currently available...
-
Heidelberg, Germany, April 2, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today provided an...
-
Heidelberg, Germany, April 1, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that...
-
Heidelberg, Germany, March 26, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that...
-
Dr. Schottelius, former executive at Kymab, MorphoSys and Genentech, brings extensive innate immunity expertise and successful record of advancing discovery research into preclinical and clinical...
-
Heidelberg, Germany, February 19, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced...
-
Heidelberg, Germany, February 3, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced...
-
Dr. Harstrick, formerly Chief Medical Officer at Molecular Partners and Senior Vice President Medical Sciences and Product Lead for Erbitux® at ImClone Systems/Eli Lilly, will lead company’s...
-
Heidelberg, Germany, December 17, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced...